Screener
Liquidia Corporation LQDA Product — Cost of Goods Sold
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Liquidia Corporation in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Liquidia Corporation’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058252
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Service revenue, net | 2,984 | 3,120 |
| Total revenue | 132,865 | 3,120 |
| Costs and expenses: | ||
| Cost of product sales | 11,079 | — |
| Cost of service revenue | 773 | 1,517 |
| Research and development | 12,571 | 6,966 |
| Selling, general and administrative | 46,938 | 30,062 |
| Total costs and expenses | 71,361 | 38,545 |
Item 1. Condensed Financial Statements (unaudited)
FAQ
- What is Liquidia Corporation's product — cost of goods sold?
- Liquidia Corporation (LQDA) reported product — cost of goods sold of $11.08M in Q1 2026.
- What does product — cost of goods sold mean?
- This metric captures the direct costs incurred to manufacture and supply the company's pharmaceutical products, including materials, labor, and overhead directly attributable to production. It is a critical measure of manufacturing efficiency and the direct profitability of the product segment. Tracking this allows for the evaluation of gross margin trends and the scalability of the company's production processes.
Ask your AI about Liquidia Corporation's product — cost of goods sold.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude